The Non-Coding RNA Ontology (NCRO): a comprehensive resource for the unification of non-coding RNA biology by Huang, Jingshan et al.
Huang et al. Journal of Biomedical Semantics  (2016) 7:24 
DOI 10.1186/s13326-016-0066-0
RESEARCH Open Access
The Non-Coding RNA Ontology (NCRO): a
comprehensive resource for the unification of
non-coding RNA biology
Jingshan Huang1*, Karen Eilbeck2, Barry Smith3, Judith A. Blake4, Dejing Dou5, Weili Huang6,
Darren A. Natale7, Alan Ruttenberg8, Jun Huan9, Michael T. Zimmermann10, Guoqian Jiang10, Yu Lin11,
Bin Wu12, Harrison J. Strachan1, Yongqun He13, Shaojie Zhang14, Xiaowei Wang15, Zixing Liu16,
Glen M. Borchert17 and Ming Tan16
Abstract
In recent years, sequencing technologies have enabled the identification of a wide range of non-coding RNAs
(ncRNAs). Unfortunately, annotation and integration of ncRNA data has lagged behind their identification. Given the
large quantity of information being obtained in this area, there emerges an urgent need to integrate what is being
discovered by a broad range of relevant communities. To this end, the Non-Coding RNA Ontology (NCRO) is being
developed to provide a systematically structured and precisely defined controlled vocabulary for the domain of
ncRNAs, thereby facilitating the discovery, curation, analysis, exchange, and reasoning of data about structures of
ncRNAs, their molecular and cellular functions, and their impacts upon phenotypes. The goal of NCRO is to serve as a
common resource for annotations of diverse research in a way that will significantly enhance integrative and
comparative analysis of the myriad resources currently housed in disparate sources. It is our belief that the NCRO
ontology can perform an important role in the comprehensive unification of ncRNA biology and, indeed, fill a critical
gap in both the Open Biological and Biomedical Ontologies (OBO) Library and the National Center for Biomedical
Ontology (NCBO) BioPortal. Our initial focus is on the ontological representation of small regulatory ncRNAs, which we
see as the first step in providing a resource for the annotation of data about all forms of ncRNAs. The NCRO ontology
is free and open to all users, accessible at: http://purl.obolibrary.org/obo/ncro.owl.
Keywords: Non-coding RNA, Biomedical ontology, Domain ontology, Reference ontology, Ontology development,
Data annotation
Introduction
It is known that non-coding RNAs (ncRNAs), a special
class of functional RNA molecules, will not be translated
into proteins. The chemical identity and first guesses as
to the role of RNA were discussed by Casperson and
Schultz back in 1939, and the first RNA structure was
reported by Alexander Rich in 1956 [1]. Since then, many
types of ncRNAs have been identified, including the now
well-known transfer RNAs (tRNAs) and ribosomal RNAs
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(rRNAs), in addition to the more recently discovered long
non-coding RNAs (lncRNAs), microRNAs (miRNAs), and
so forth. Many ncRNAs perform important roles in the
realization of a wide range of molecular functions as well
as in affecting many different biological and patholog-
ical processes. As such, interest in ncRNA biology has
grown throughout biomedicine, biomedical informatics,
and clinical sciences. In addition, the fertile area of ncRNA
research has been significantly enhanced in recent years
by new sequencing technologies that have generated con-
tinuously increasing quantities of available data. However,
annotation and integration of data about ncRNAs, the
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functions regulated by ncRNAs for example, has lagged
behind their identification, resulting in an urgent need for
effective methodologies to bring together discoveries con-
tinuously deriving from different segments of the ncRNA
research community.
Emerging semantic technologies provide computational
methodologies that promote more precise communica-
tion among scientists, enable more effective information
retrieval and integration across diverse resources, and
extend the power of computational technologies to per-
form data exploration, inference, and mining [2–7]. In
particular, the sorts of reasoning (inference) enabled by
semantic technologies are not available where we are
confined to traditional relational database systems or text-
based search and query. By placing more emphasis on the
semantics (i.e., the intended meaning) of data, semantic
technologies and domain ontologies enable us to estab-
lish more meaningful connections among original data,
thereby helping to bridge gaps in our knowledge. More-
over, semantic data connections are established in a highly
flexible manner that allows these connections to be much
more easily extended — for example when new sorts of
entities are discovered — than is possible using more
traditional approaches.
Among all successful efforts in applying semantic tech-
nologies in the biomedical domain, the Open Biological
and Biomedical Ontologies (OBO) Library [8] is of spe-
cial importance in that it has served as an umbrella
for different ontologies shared across various biologi-
cal, biomedical, and clinical domains. However, there has
until now existed in the OBO Library no comprehensive
ontologies specifically designed for the ncRNA domain,
although portions of the domain are catalogued in several
orthogonal ontologies. The National Center for Biomedi-
cal Ontology (NCBO) BioPortal [9], a repository of biolog-
ical and biomedical ontologies (short for bio-ontologies),
is another effort in some ways parallel to the OBO Library
but with a broader scope and lower hurdles for admis-
sion. However the BioPortal, too, contains, no compre-
hensive ncRNA ontologies. These observations indicate
that there is an important gap that needs to be filled —
hence the Non-Coding RNA Ontology (NCRO) project.
As the first comprehensive, domain-specific ontology in
the ncRNA field, the NCRO ontology aims to supply
a systematically structured, precisely defined controlled
vocabulary for the ncRNA domain, consisting of a set
of common, standardized terms and relations that will
facilitate the discovery, curation, analysis, exchange, and
reasoning of data about the structures, functions, and
molecular, cellular, organismal, therapeutic, or biotechno-
logical uses of ncRNAs. The NCRO ontology can serve
as a resource for annotating and integrating ncRNA data
produced by diverse communities, thereby significantly
enhancing integrative and comparative analysis of the
myriad resources currently housed in disparate sources.
We believe that the NCRO will help to address a vital
need for the comprehensive unification of ncRNA biol-
ogy. We aim to integrate genomic and sequence-based
annotation with gene expression regulation, secondary
and 3D structure information, protein interactions, and
their inter-relationships. Our initial focus is on the onto-
logical representation of small regulatory ncRNAs, which
we see as the first step in providing a standardized
resource for (1) annotating data about all forms of ncR-
NAs and (2) facilitating knowledge capture in the ncRNA
domain.
The rest of this paper is organized as follows.
Section ‘Related work’ summarizes state-of-the-art
research in ncRNAs and bio-ontologies; Section
‘Ontology scope’ gives an overview of the scope covered
by the NCRO ontology; Section ‘Ontology development’
introduces NCRO development principles and proce-
dure; Section ‘NCRO terms, relations, and reasoning’
describes NCRO terms and relations, as well as ontology
reasoning; Section ‘Examples in NCRO annotations’
presents two examples to demonstrate how NCRO
annotations and ontology reasoning can be performed to
facilitate knowledge capture; finally, Section ‘Conclusions’
concludes with future research directions.
Related work
Related work in ncRNA research
Prior research, [10–12] for example, has uncovered
numerous ncRNA genes, and recent advances in next gen-
eration sequencing technology have resulted in an even
greater number and faster pace of discovery of ncRNA
genes. In fact, Nature has a whole site dedicated to key
apes in this area [13]. Given the relatively large propor-
tion of the genome dedicated to ncRNA genes, significant
potential exists to explore ncRNAs that may have diverse
biological roles.
Abnormal expression of some ncRNAs is involved
in human disease. For example, alterations of gene-
regulatory ncRNA expression are involved in the
development, progression, and metastases of human can-
cer [14]. When differentially expressed gene-regulatory
ncRNAs play roles in altering target gene expression,
further phenotypic effects can be realized. Differential
expression of such ncRNAs in malignant versus nor-
mal tissue can be exploited as a biomarker used for
diagnosis, prediction of patient outcome, or monitor-
ing the effectiveness of cancer therapeutics. Therefore,
these gene-regulatory ncRNAs are potential therapeu-
tic targets for cancer therapy. In recent years serious
attempts have been made to effectively deliver ncRNA
into tumors in animal models. Some of the attempts have
already shown promising therapeutic efficacy [15–17].
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In RNA interference therapy and drug development,
a first-in-human trial has been conducted in cancer
patients who were administered with lipid nanoparticles
(LNP) formulated siRNA targeting VEGF and
KSP [18].
Aberrant expression of ncRNAs has been associated
with not only cancers but also numerous other dis-
eases, including autism, hearing loss, Alzheimer’s disease,
Prader-Willi Syndrome, diabetes, and psoriasis [19–23].
Tissue-specific miRNAs have been shown to be involved
in cardiovascular, muscular, and neurodegenerative dis-
eases, and pharmaceutical companies are developing new
therapeutic molecules that alter the function or expres-
sion of specific miRNAs for treating these and other
human diseases [24].
Related work in bio-ontologies
There are several pre-existing bio-ontologies that are rel-
evant to the development of an ontology in the domain of
functional non-coding RNA. The RNAOntology (RNAO)
[25] is a reference ontology created to catalogue the
molecular entities composing primary, secondary, and
tertiary components of RNA. The goal of the RNAO
project is to enable integration and analysis of diverse
RNA datasets. The Gene Ontology (GO) [26] is by far the
most successful and widely used bio-ontology, consisting
of three independent sub-ontologies: biological processes,
molecular functions, and cellular components. The GO
has been utilized to annotate both protein and RNA
gene products across multiple organisms. The Sequence
Ontology (SO) [27] is an ontology that is designed to cap-
ture genomic features and the relationships that obtain
between them. This ontology contains the features nec-
essary to annotate a genome sequence with structural
features such as gene models and also the terms nec-
essary for the annotation of the location and extent of
genomic variants. The PRotein Ontology (PRO) [28] has
been developed with a particular focus on human pro-
teins and disease-related variants thereof, providing an
ontological representation of proteins. As proteins are
often the functional entities in the processes impacted
by the regulatory effect of ncRNAs, they are an impor-
tant factor in the understanding of ncRNA. The Ontol-
ogy for MIcroRNA Target (OMIT) [29–31] is a miRNA
domain ontology that is being developed as part of the
OmniSearch project. The purpose is to establish standard
metadata in miRNA domain for more effective identifica-
tion of the roles of miRNAs in various human diseases.
The ontology of Chemical Entities of Biological Interest
(ChEBI) [32] provides the terminology and relationships
to describe small molecules.
There are also other bio-ontologies that are in use in
a wider context that are also important for the descrip-
tion of clinical impact of ncRNA. SNOMED CT [33] is
a comprehensive, clinically oriented medical terminology
system, and also a reference standard in the United
States Meaningful Use program that promotes the use
of certified electronic health record (EHR) technol-
ogy to improve quality, safety, and efficiency, as well
as to reduce health disparities [34]. SNOMED CT is
owned andmaintained by the International Health Termi-
nology Standard Development Organization (IHTSDO).
Anatomy description has been unified over multiple
species with the Uberon anatomical Ontology [35]. This
ontology relates taxon-specific anatomies and is fully
integrated with other bio-ontologies such as the GO.
The Human Disease Ontology (DOID) [36] encapsu-
lates the terminology of diseases and provides equivalent
mappings to many related terminologies. The NCI The-
saurus (NCIt) [37] is a reference biomedical ontology
published by the National Cancer Institute (NCI) with
terminology that includes clinical care, translational and
basic research, and public information and administrative
activities.
Additionally, there are ontologies that address the
domain of data collection and are pertinent to the under-
standing of ncRNA. An ontology that covers the domain
of translational research is the Ontology of Biomedical
Investigations (OBI) [38], describing the foundational ter-
minology needed to define experimental processes and
investigation. Moreover, the Information Artifact Ontol-
ogy (IAO) [39] arose as a branch of OBI, to define the
foundational entities of scientific information in the digi-
tal domain.
Note that all bio-ontologies described in this section
except for SNOMED CT are included in both the OBO
Library and NCBO BioPortal. SNOMED CT is included
only in the BioPortal.
Ontology scope
The NCRO ontology will represent:
1. All known subtypes of ncRNA molecules including
those created in living organisms as well as those
engineered or adapted for some purposes (aptamers
for example [40]) — this aspect will utilize high-level
terms defined in both the SO and ChEBI, with more
specific terms defined in the NCRO;
2. The structure involved in each ncRNA type,
including sequence and conformation — this aspect
will utilize the RNAO;
3. The functions, dispositions, and roles of ncRNAs, as
well as the processes in which these are realized1 —
this aspect will utilize, mostly, the GO, with gaps
specific to ncRNAs filled by the NCRO or other
ontologies;
4. Different clinical phenotypes associated with
expression of normal and/or abnormal ncRNAs —
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this aspect will utilize the SNOMEDCT, NCIt, and
Human Disease Ontology (DOID); and finally,
5. Various relations that are unique to ncRNAs and
their different components.
The initial focus of our work in building the ontol-
ogy is on small regulatory ncRNAs. Nevertheless, we
have designed an overarching framework of high-level
terms for other ncRNAs, such as: circular RNA (circRNA),
lncRNA, rRNA, small interfering RNA (siRNA), small
nuclear RNA (snRNA), and tRNA. These high-level terms,
all of which are direct child terms of the term “ncRNA,”
serve as placeholders: a more detailed hierarchy under-
neath each term, along with relevant relations, will be
developed at a later project stage.
Ontology development
Development principles
In the development pipeline for the NCRO ontology,
we have observed a set of practices proposed by the
OBO Foundry Initiative [41, 42]. Above all, the ontol-
ogy should be: freely available; expressed in a standard
language; documented for successive versions; orthogonal
to existing ontologies; including natural language specifi-
cations; developed collaboratively; and used by multiple
researchers.
Compliance with established upper-level ontologies
All NCRO terms descend from terms defined in the Basic
Formal Ontology (BFO) v2.0 [43]. The BFO is a small,
upper-level ontology that is designed for use in sup-
porting information retrieval, analysis, and integration in
scientific and other domains. Because the BFO is a well-
established upper ontology adopted by all OBO ontolo-
gies, our strategy to make the NCRO a BFO-compliant
ontology will set the stage for interoperability between
the NCRO ontology and other currently existing OBO
ontologies.
As for relations, besides those defined in the NCRO,
we have also used a set of well-defined relations in the
Relation Ontology (RO) [44, 45], such as: “part of,” “par-
ticipates in,” and “precedes,” all of which relate different
types defined in the BFO. Greater details of various rela-
tions can be found in Section ‘NCRO terms and relations’
and Table 3.
Strategy for orthogonality
Out of the set of OBO Foundry principles, orthogo-
nality is of special importance in defining the novelty
of the NCRO ontology. Our strategy to abide by this
principle is that we have imported and reused extant
terms wherever possible, focusing especially on terms
from OBO ontologies, SO, GO, PRO, and ChEBI for
example. Such terms have been imported with their
original identifier information using internationalized
resource identifiers (IRIs)/uniform resource identifiers
(URIs). This strategy helps us to achieve the maximum
possible orthogonality. Table 1 demonstrates a subset of
imported terms. More details can be found in Section
‘NCRO terms, relations, and reasoning,’ where per-
centages of imported terms from various existing bio-
ontologies are calculated.
The NCRO team and domain expertise
The NCRO team members come from a wide variety of
communities, covering computer science, ontology engi-
neering, wet-lab biological research, biomedical informat-
ics, and clinical sciences. The wide scope of participants
will provide (1) the necessary expertise in ontology devel-
opment and ontology-based reasoning and (2) the ncRNA
domain knowledge including expertise in ncRNA-relevant
phenotype. It will also help to ensure (3) a diversity of
communities eager to adopt the NCRO ontology for use
in representing and annotating ncRNA data.
Dynamic ontology construction procedure
The NCRO development is from the top down (start-
ing with more general terms), progressively utilizing
the ncRNA domain knowledge provided by the cellu-
lar biologists and clinical investigators in the project
Table 1 A subset of terms imported into the NCRO ontology
Imported term Source Ontology Original ID
miRNA Sequence Ontology SO:0000276
ncRNA Sequence Ontology SO:0000655
small_regulatory_ncRNA Sequence Ontology SO:0000370
gene Sequence Ontology SO:0000704
promoter Sequence Ontology SO:0000167
binding Gene Ontology GO:0005488
transcription, Gene Ontology GO:0006351
DNA-templated
translation Gene Ontology GO:0006412
metabolic_process Gene Ontology GO:0008152
protein PRotein Ontology PR:000000001
organism Ontology for OBI:0100026
Biomedical Investigations
cell Gene Ontology GO:0005623
cell line Cell Line Ontology CLO:0000031
molecular entity Chemical Entities of CHEBI:23367
Biological Interest Ontology
organ Uber Anatomy Ontology UBERON:0000062
tissue Uber Anatomy Ontology UBERON:0000479
disease Human Disease Ontology DOID:4
Huang et al. Journal of Biomedical Semantics  (2016) 7:24 Page 5 of 12
team. Lower levels of the ontology were then further
developed on the basis of a thorough analysis of repre-
sentative ncRNA-related databases (Table 2). Moreover,
an iterative procedure, including a series of interviews,
exchanges of documents, refinements, and related doc-
umentations, is being followed to make the NCRO a
dynamic ontology. In addition to a dedicated project
website [46], we have utilized GitHub [47] to further
assist the management and version control of the ontol-
ogy during both design and implementation, including
an established issue tracker [48] to facilitate discus-
sion among the members of an open group of investi-
gators, so that OBO Foundry principles can be better
followed.
Naming conventions
Each NCRO term has a unique identifier consisting
of a prefix and seven digit numerical string, as in:
NCRO_0000001. On the other hand, each NCRO term is
also assigned a human-readable label. We have followed
a set of OBO Foundry naming conventions [49] to design
such labels. Specifically:
• Labels are written in lower cases except for commonly
accepted acronyms such as “RNA” and “ncRNA.”
• Hypens are kept as is if they are commonly used in, or
easily understood by, the ncRNA community, as in:
“hsa-miR-125b.”
For greater readability, we italicize all relations through-
out this paper, whether they are defined in the NCRO or
imported from the RO and BFO.
Ontology languages and development tools
We have chosen both the Web Ontology Language
(OWL) [50] and OBO formats to describe the ontol-
ogy: both are widely accepted in OBO Foundry com-
munity and the former is recommended by the World
Wide Web Consortium (W3C). A first version of the
ontology was authored in OBO-Edit [51] and trans-
lated to OWL by the ROBOT tool [52]; then the
OWL version has been subsequently edited. Moving for-
ward, our focus will be placed on editing and releas-
ing the OWL version to take advantage of OWL-
specific features such as availability of ontology reasoners
and triple stores, as well as enhanced annotation
expressivity.
NCRO terms, relations, and reasoning
NCRO terms and relations
The current version NCRO (http://purl.obolibrary.org/
obo/ncro.owl) is our first production release. There
are a total of 3,078 terms and 27 relations (besides
a total of 5,394 is_a relations). Terms break down as
follows: 82.68% were defined in the NCRO ontology
itself, and the rest were imported from extant ontolo-
gies: BFO (1.14%), GO (8.67%), SO (6.50%), PRO
(0.10%), CHEBI (0.29%), OBI (0.13%), IAO (0.06%),
DOID (0.13%), CLO (0.06%), and UBERON (0.16%).
As for relations, many (55.56%) were imported from
the RO, and the rest (51.03%) were defined in the
NCRO.
Orthogonality among different ontologies has been
widely accepted in the bio-ontology community. To
achieve better orthogonality, it is a common practice to
reuse contents defined in relevant, existing ontologies.
This is our motivation to import terms and relations
from extant ontologies, as demonstrated above. On the
other hand, it is not trivial to obtain 100% orthogo-
nality, because ontologies are continuously being devel-
oped for good reasons within specific domains and by
different groups. As a result, given the holistic nature
of biology, along with the fact that different applica-
tions most likely have adopted different development
methodologies and have focused on various emphases,
Table 2 A list of ncRNA-related databases
Database name Brief introduction Web link
Ensembl ncRNA A database of ncRNA annotations. http://www.ensembl.org/info/
genome/genebuild/ncrna.html
GENCODE A database for annotation of gene features. http://www.gencodegenes.org
lncRNAdb A reference database for functional lncRNAs. http://www.lncrnadb.org
lncRNAtor A Web portal encompassing lncRNA data. http://lncrnator.ewha.ac.kr
miRBase A database of miRNA sequences and annotation. http://www.mirbase.org/
NDB A database of experimentally determined nucleic acids. http://ndbserver.rutgers.edu
NONCODE A database of ncRNAs except for tRNAs and rRNAs. http://www.noncode.org/
NRED An ncRNA expression database. http://nred.matticklab.com/cgi-bin/ncrnadb.pl
Rfam A database of a collection of RNA families. http://rfam.xfam.org
RMDB Chemical Mapping Data of RNA Sequences. https://rmdb.stanford.edu
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there will inevitably be some overlaps among ontolo-
gies regarding their covered terms and/or relations. For
example, the term “analgesic_treatment” defined in the
NCRO2 is similar with the term “analgesic treatment”
defined in the Malaria Ontology3. Such overlaps may
have negative impacts on logical inferencing if ontol-
ogy reasoning is performed across relevant ontologies.
Whereas it is not realistic, if not impossible at all, to
obtain “pure” (i.e., 100%) orthogonality, one effective way
to handle this situation is to add cross-references in the
ontologies.
Details of all terms and relations in the NCRO ontol-
ogy are publicly available [46, 47]. In addition, Table 3
presents a subset of relations defined in or imported
into the NCRO; and Fig. 1 shows a complete view
of the core portion designed in the ontology, using
the format of “PREFIX:label” to describe each term or
relation.
Ontology reasoning
The NCRO ontology provides a standardized, well-
structured, and precisely defined set of terms, along with
various relations among these terms. The NCRO thus:
• Enables machine-readable description and encoding
of ncRNA annotations — so that these annotations
can be identified and integrated in a more precise and
effective manner.
• Helps establish connections among diverse ncRNA-
related data sources — through cross-references that
are formally defined in the expert-built NCRO
ontology and other extant domain bio-ontologies.
• Provides necessary software substrates for automated
ontology reasoning — (1) annotated data can be
more readily verified through validating internal
consistency and (2) further, insights for new
discoveries can be effectively derived through
inferred relations and more expressive queries.
In this way, the NCRO ontology assists in establish-
ing ncRNA common data elements and data exchange
standards. Consequently, it will greatly enhance data
sharing and exchange as well as comparative analysis
on ncRNA annotations from heterogeneous sources. In
addition, because the NCRO ontology covers species
other than Homo sapiens, it will enable communication
among different model organism groups. The next section
contains greater details on how NCRO-based ontol-
ogy reasoning can further facilitate ncRNA knowledge
capture.
Examples in NCRO annotations
Wedescribe below two examples designed to demonstrate
how NCRO annotations and NCRO-based ontology rea-
soning can be performed. The first example is based on
Table 3 A subset of relations defined in or imported into the NCRO ontology
Relation Domain Range Explanation
NCRO:is_classified_into miRNA miRNA_gene_family Each miRNA can be classified
_gene_family_group into some gene family.
NCRO:miRNA_expressed miRNA_expression tissue miRNAs can be expressed in some
_in_tissue specific tissues.
NCRO:regulate_mRNA miRNA_expression translation miRNAs can regulate the translation
_translation process of some mRNAs.
NCRO:regulate_miRNA protein transcription_of_miRNA Proteins can regulate the
_transcription transcription process of some miRNAs.
NCRO:is_model_of_disease material entity disease A cell line is a model of some disease.
RO:participates in gene transcription, A gene participates in the regulation
DNA-templated of some transcription.
RO:participates in miRNA_target_gene miRNA_and_target_ A link to connect a miRNA and its
miRNA gene_binding likely target gene.
RO:participates in promoter_of_miRNA protein_miRNA_ Connection between the miRNA
protein promoter_binding promoter and protein.
RO:precedes protein_miRNA_ miRNA_ Protein-promoter binding happens
promoter_binding transcription_initiation before the transcription.
RO:precedes miRNA_transcription_ transcription_of_miRNA Transcription initiation happens before
initiation the transcription process.
RO:part of organ organism An organ is part of some organism.
RO:part of cell organ A cell is part of some organ.
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Fig. 1 NCRO core terms and relations. The design of core terms and relations in the NCRO ontology (terms and relations are represented in the
format of “PREFIX:label”)
important findings reported in Ma et al. (shown in Fig. 2,
bottom-left corner):
• hsa-miR-10b binds to its target, Hox-D10 gene, which
participates in regulation of Hox-D10 transcription.
• Hox-D10 transcription is found in MDA-MB-231 cell
line, which is a model of metastatic breast cancer.
• The transcription of hsa-miR-10b itself is found in
MDA-MB-231 cell line.
• The details of hsa-miR-10b transcription process are:
(1) a protein, TWIST1, binds to E-box1, a promoter of
hsa-miR-10b; (2) such a binding leads to an initiation
of hsa-miR-10b transcription; and finally, (3)
hsa-miR-10b transcription occurs in MDA-MB-231
cell line under the regulation of TWIST1.
These findings can be annotated with NCRO terms and
relations, and the annotation result is shown in Fig. 2.
Note that for reasons of clarity only relevant terms and
relations are shown. Appropriate ontology terms were
related to the above-mentioned findings, demonstrated
as a set of leaf nodes in bold, brown color in the figure.
For example,Hox-D10 gene was annotated with the term
“NCRO:miRNA_target_gene,” hsa-miR-10b E-box 1 was
annotated with the term “NCRO:promoter_of_miRNA,”
and metastatic breast cancer was annotated with the
term “DOID:disease.” It is evident that the original,
human-readable information contained in the paper was
precisely annotated and converted into NCRO-compliant,
machine-understandable knowledge, which can be
readily represented in appropriate computer-friendly
formats, resource description framework (RDF) triples for
example.
Next, ontology reasoning can be performed on such
machine-understandable knowledge to not only auto-
matically verify the encoded knowledge but also —
equally importantly — infer new knowledge that was
originally hidden and inexplicit in the raw data. For
example:
1. Reasoning based on the is_a hierarchy from
hsa-miR-10b all the way to “SO:miRNA” as well as
reasoning based on the participates in relation will
lead to Conclusion 1: hsa-miR-10b binds to its
targetHox-D10 gene.
2. Similarly, another conclusion can be readily obtained
as well, that is, Conclusion 2: “Hox-D10 gene
participates inHox-D10 transcription.”
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Fig. 2 Step one in use case I. NCRO Annotation Use Case I (Step One— ontology-based annotation)
Figure 3 demonstrates the conclusions obtained fol-
lowing such reasoning mechanisms. In this example,
based on a piece of domain knowledge defined in the
NCRO ontology, “the gene family group of hsa-miR-
10b is MIPF0000033: mir-10 family,” we can infer a new
hypothesis that the mir-10 family is likely to par-
ticipate in the control and regulation of metastatic
breast cancer disease process. Note that this hypoth-
esis, drawn by ontology reasoning, was not explicitly
stated in the original paper; at the same time, it pro-
vides an important clue to both cancer biologists and
clinical investigators for wet-lab experiment design and
treatment planning, respectively. As discussed earlier in
Section ‘Introduction,’ these reasoning mechanisms are
not possible in any traditional relational database sys-
tems or conventional text-based search and query. In
fact, this is one of the reasons why semantic technolo-
gies and domain ontologies have been playing increasingly
important roles in biological and biomedical knowledge
capture — by placing more emphasis on the semantics
(i.e., the intended meaning) of data, semantic technolo-
gies and domain ontologies enable us to establish newly
discovered, more meaningful connections among origi-
nal data, which in turn help to bridge gaps in human
knowledge.
A second annotation example is demonstrated in
Fig. 4: hsa-miR-200b is shown to be closely related to
metastatic hepatocellular carcinoma; similarly, we can
infer a new hypothesis that the mir-200 family is likely
to participate in the control and regulation of metastatic
hepatocellular carcinoma.
Conclusions
Prior research has indicated that ncRNAs perform impor-
tant roles in realizing a wide range of molecular functions
and affecting many different biological and pathologi-
cal processes. Interest in ncRNA biology has therefore
grown throughout biomedicine, biomedical informatics,
and clinical sciences in recent years. Due to the lack of
standardized ncRNA nomenclature, there exist significant
barriers to the representation, acquisition, integration,
and comparison of ncRNA data. Thus, the establish-
ment of common data elements and data exchange stan-
dards for the ncRNA domain is an important need. The
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Fig. 3 Step two in use case I. NCRO Annotation Use Case I (Step Two— ontology reasoning)
OBO Library has successfully served as an umbrella for
different communities of ontologists drawn from a variety
of biomedical and clinical domains. Until now, however,
the OBO Library contained no ontologies designed for
the ncRNA domain. Likewise, the NCBO BioPortal lacked
such ontologies. We developed the NCRO ontology to fill
this important gap. The NCRO aims to provide a system-
atically structured, precisely defined ncRNA controlled
vocabulary, including a set of common, standardized
terms and relations, to facilitate the discovery, curation,
analysis, exchange, and reasoning of data about ncRNA
structures, functions, and uses. The ultimate goal of the
NCRO project is to establish a virtual center to further
facilitate knowledge capture about all forms and uses of
ncRNAs.
In this paper, we introduced the scope, development
process, and core terms and relations in the NCRO
ontology. We also discussed reasoning mechanisms to
further facilitate ncRNA data management, including
data annotation, analysis, comparison, and integration.
The examples provided showcase how NCRO annota-
tions and NCRO-based ontology reasoning can be per-
formed to assist cellular biologists, bioinformaticians, and
clinical investigators in ncRNA-related knowledge acqui-
sition and discovery. As a common resource for anno-
tations of diverse ncRNA research, the NCRO ontology
can perform an important role in the comprehensive
unification of ncRNA biology. This unification inte-
grates genomic and sequence-based annotation with gene
expression regulation, secondary and 3D structure infor-
mation, protein interactions, and their inter-relationships,
using standardized ontological representations. The cur-
rent version of the NCRO ontology contains a total of
3,078 terms and 27 relations (besides a total of 5,394
is_a relations). The ontology files and design documenta-
tions are publicly available at: OBO Library [53], NCBO
BioPortal [54], and GitHub [47]. In addition, we also
developed a dedicated project website [46]. Note that
the most up-to-date ontology file is always accessible at:
http://purl.obolibrary.org/obo/ncro.owl.
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Fig. 4 Step two in use case II. NCRO Annotation Use Case II (Step Two— ontology reasoning)
The initial focus of the NCRO project is on small reg-
ulatory ncRNAs; on the next stage of development we
will move to other ncRNA terms and associated relations,
using the high-level placeholders that are already defined
in the NCRO ontology.
Endnotes
1For instance, off-target effects are represented as the
realization of dispositions. We will focus on processes
related to natural biology, or on processes intended to
modulate natural biology like in therapeutic or
experimental use of ncRNAs.
2http://purl.obolibrary.org/obo/NCRO_0000229.
3http://purl.obolibrary.org/obo/IDOMAL_0000267.
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